Page last updated: 2024-09-05

iclaprim and Adverse Drug Event

iclaprim has been researched along with Adverse Drug Event in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Dryden, M; Huang, DB	1

Reviews

1 review(s) available for iclaprim and Adverse Drug Event

Article	Year
Iclaprim, a dihydrofolate reductase inhibitor antibiotic in Phase III of clinical development: a review of its pharmacology, microbiology and clinical efficacy and safety. Future microbiology, 2018, Volume: 13 Topics: Administration, Intravenous; Anti-Bacterial Agents; Clinical Trials, Phase III as Topic; Drug-Related Side Effects and Adverse Reactions; Folic Acid Antagonists; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pyrimidines; Skin Diseases, Bacterial; Treatment Outcome	2018

Article

Year

Iclaprim, a dihydrofolate reductase inhibitor antibiotic in Phase III of clinical development: a review of its pharmacology, microbiology and clinical efficacy and safety.

Future microbiology, 2018, Volume: 13

Topics: Administration, Intravenous; Anti-Bacterial Agents; Clinical Trials, Phase III as Topic; Drug-Related Side Effects and Adverse Reactions; Folic Acid Antagonists; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pyrimidines; Skin Diseases, Bacterial; Treatment Outcome

2018